Takeda Signs a Multi-Target Agreement with StrideBio to Develop Gene Therapies for Neurological Disorders

 Takeda Signs a Multi-Target Agreement with StrideBio to Develop Gene Therapies for Neurological Disorders

Takeda Signs a Multi-Target Agreement with StrideBio to Develop Gene Therapies for Neurological Disorders

 Shots:

  • StrideBio to receive $30M upfront & near term pre-clinical milestones, $680M as development and commercial milestones & royalties on global sales of products. Takeda to get rights for clinical development and commercialization of selected products developed
  • StrideBio will take care of preclinical development & manufacturing of in vivo AAV based gene-therapies for Takeda’s three targets including Friedreich’s Ataxia (FA)
  • StrideBio’s gene therapy technology is used to develop adeno-associated viral (AAV) therapies for rare diseases able to evade pre-existing antibodies. In 2018, Takeda Ventures funded Stride Bio for the development of AAV technology

Click here to read full press release/ article | Ref: Mitsubishi Tanabe Pharma | Image: MGH

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post